▲ Sejong Government Complex of the Ministry of Health and Welfare
The Ministry of Health and Welfare announced that it has selected five drugs for the pilot program aimed at the rapid health insurance listing of rare disease treatments following a public call for applications and evaluations.
The selected drugs are "Spevigo Injection" for generalized pustular psoriasis, "Agamree Oral Suspension" for Duchenne muscular dystrophy, "Joenja Tablet" for activated phosphoinositide 3-kinase delta (PI3K) syndrome, "Qalsody Injection" for amyotrophic lateral sclerosis, and "Iqirvo Tablet" for primary biliary cholangitis.
The fast-track listing pilot program was introduced to improve treatment accessibility for critically ill patients who lack alternative treatments, even though securing clinical evidence is difficult due to the small number of patients characteristic of rare diseases.
Notably, the key aspect is that the cost-effectiveness evaluation, which must normally be conducted before health insurance listing, is converted into a post-evaluation.
The selected drugs must complete their application for listing by January next year at the latest, following procedures such as supplementing the post-evaluation plan and submitting performance agreements.
(Photo provided by the Ministry of Health and Welfare, Yonhap News)
※
Copying, redistribution, and unauthorized use in AI training are strictly prohibited.